- Joined
- Dec 3, 2017
- Messages
- 26,290
- Reaction score
- 16,771
- Gender
- Male
- Political Leaning
- Progressive
New TB Vaccine Could Save Millions of Lives, Study Suggests - The New York Times
There are 10 million new cases each year of tuberculosis, now the leading infectious cause of death worldwide. Even a partly effective vaccine could help turn the tide.
In what may be a watershed moment in the fight against tuberculosis, the world’s most lethal infectious disease, an experimental new vaccine has protected about half the people who got it, scientists reported on Tuesday.
While a 50 percent success rate is hardly ideal — the measles vaccine, by contrast, is about 98 percent protective — about 10 million people get tuberculosis each year, and 1.6 million die of it. Even a partly effective vaccine may save millions of lives.
========================================================
Sounds like a potential winner.
'The new vaccine, made by GSK and now known as M72/AS01E, was tested in about 3,300 adults in Kenya, South Africa and Zambia. All of them already had latent tuberculosis — a silent infection that might or might not progress to active tuberculosis.
Of those who got two doses of the GSK vaccine, only 13 developed active tuberculosis during three years of follow-up.'
There are 10 million new cases each year of tuberculosis, now the leading infectious cause of death worldwide. Even a partly effective vaccine could help turn the tide.
In what may be a watershed moment in the fight against tuberculosis, the world’s most lethal infectious disease, an experimental new vaccine has protected about half the people who got it, scientists reported on Tuesday.
While a 50 percent success rate is hardly ideal — the measles vaccine, by contrast, is about 98 percent protective — about 10 million people get tuberculosis each year, and 1.6 million die of it. Even a partly effective vaccine may save millions of lives.
========================================================
Sounds like a potential winner.
'The new vaccine, made by GSK and now known as M72/AS01E, was tested in about 3,300 adults in Kenya, South Africa and Zambia. All of them already had latent tuberculosis — a silent infection that might or might not progress to active tuberculosis.
Of those who got two doses of the GSK vaccine, only 13 developed active tuberculosis during three years of follow-up.'